Dr James Stone

Publications


Journals

  • Carhart-Harris RL; Erritzoe DE; Williams TM; Stone JM; Leech R; Reed L; Colasanti A; Tyacke R; et alMalizia A; Evans J; Hobden P; Murphy K; Feilding A; Wise RG; Nutt DJ. (2012). The neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences of USA.
  • Carhart-Harris RL; Erritzoe D; Williams T; Stone JM; Reed LJ; Colasanti A; Tyacke RJ; Leech R; et alMalizia AL; Murphy K; Hobden P; Evans J; Feilding A; Wise RG; Nutt DJ. (7 Feb 2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 109:2138-2143. DOI.
  • Egerton A; Stone JM. (26 Jan 2012). The glutamate hypothesis of schizophrenia: Neuroimaging and drug development. Curr Pharm Biotechnol.
  • Egerton A; Fusar-Poli P; Stone JM. (2012). Glutamate and psychosis risk. Curr Pharm Des. 18:466-478.
  • Stone JM; Dietrich C; Edden R; Mehta MA; De Simoni S; Reed LJ; Krystal JH; Nutt D; et alBarker GJ. (3 Jan 2012). Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry. DOI.
  • Stone JM; Morrison PD; Brugger S; Nottage J; Bhattacharyya S; Sumich A; Wilson D; Tunstall N; et alFeilding A; Brenneisen R; McGuire P; Murray RM; ffytche DH. (2011). Communication breakdown: delta-9 tetrahydrocannabinol effects on pre-speech neural coherence. Mol Psychiatry. DOI.
  • Fusar-Poli P; Stone JM; Broome MR; Valli I; Mechelli A; McLean MA; Lythgoe DJ; O'Gorman RL; et alBarker GJ; McGuire PK. (1 Sep 2011). Thalamic Glutamate Levels as a Predictor of Cortical Response During Executive Functioning in Subjects at High Risk for Psychosis. ARCHIVES OF GENERAL PSYCHIATRY. 68:881-890. Author weblink DOI.
  • Stone JM; Bhattacharyya S; Barker GJ; McGuire PK. (7 Jul 2011). Substance use and regional gray matter volume in individuals at high risk of psychosis. Eur Neuropsychopharmacol. DOI.
  • Mechelli A; Riecher-Rössler A; Meisenzahl EM; Tognin S; Wood SJ; Borgwardt SJ; Koutsouleris N; Yung AR; et alStone JM; Phillips LJ; McGorry PD; Valli I; Velakoulis D; Woolley J; Pantelis C; McGuire P. (May 2011). Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. Arch Gen Psychiatry. 68:489-495. DOI.
  • Stone JM; Howes OD; Egerton A; Kambeitz J; Allen P; Lythgoe DJ; O'Gorman RL; McLean MA; et alBarker GJ; McGuire P. (1 Jul 2011). Reply to: Hippocampal Glutamate Levels and Striatal Dopamine D(2/3) Receptor Occupancy in Subjects at Ultra High Risk of Psychosis. Biol Psychiatry. 70:e3-e4. DOI.
  • Brugger S; Davis JM; Leucht S; Stone JM. (1 Mar 2011). Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis. Biol Psychiatry. 69:495-503. DOI.
  • Morrison PD; Nottage J; Stone JM; Bhattacharyya S; Tunstall N; Brenneisen R; Holt D; Wilson D; et alSumich A; McGuire P; Murray RM; Kapur S; Ffytche DH. (1 Mar 2011). Disruption of Frontal Theta Coherence by Delta(9)-Tetrahydrocannabinol is Associated with Positive Psychotic Symptoms. NEUROPSYCHOPHARMACOLOGY. 36:827-836. Author weblink DOI.
  • Stone JM; Morrison PD; Nottage J; Bhattacharyya S; Feilding A; McGuire PK. (Aug 2010). Delta-9 tetrahydrocannabinol disruption of time perception and of self-timed actions. Pharmacopsychiatry. 43:236-237.
  • Stone JM; Howes OD; Egerton A; Kambeitz J; Allen P; Lythgoe DJ; O'Gorman RL; McLean MA; et alBarker GJ; McGuire PK. (Oct 2010). Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. BIOL PSYCHIAT. 68:599-602.
  • Stone JM. (Feb 2011). Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?. Therapeutic Advances in Psychopharmacology. 1:5-18. DOI.
  • Valli I; Stone J; Mechelli A; Bhattacharyya S; Raffin M; Allen P; Fusar-Poli P; Lythgoe D; et alO'Gorman R; Seal M; McGuire P. (1 Jan 2011). Altered Medial Temporal Activation Related to Local Glutamate Levels in Subjects with Prodromal Signs of Psychosis. BIOLOGICAL PSYCHIATRY. 69:97-99. DOI.
  • Stone JM; Abel KM; Allin MP; van Haren N; Matsumoto K; McGuire PK; Fu CH. (Jan 2011). Ketamine-induced disruption of verbal self-monitoring linked to superior temporal activation. Pharmacopsychiatry. 44:33-48. DOI.
  • Morrison PD; Stone JM. (1 Jan 2011). Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL. 26:77-80. Author weblink DOI.
  • Stone JM; Bramon E; Pauls A; Sumich A; McGuire PK. (30 Aug 2010). Thalamic neurochemical abnormalities in individuals with prodromal symptoms of schizophrenia - relationship to auditory event-related potentials. Psychiatry Res. 183:174-176. DOI.
  • Stone JM; Raffin M; Morrison P; McGuire PK. (Jul 2010). Review: The biological basis of antipsychotic response in schizophrenia. J Psychopharmacol. 24:953-964. DOI.
  • Bhattacharyya S; Morrison PD; Fusar-Poli P; Martin-Santos R; Borgwardt S; Winton-Brown T; Nosarti C; O' Carroll CM; et alSeal M; Allen P; Mehta MA; Stone JM; Tunstall N; Giampietro V; Kapur S; Murray RM; Zuardi AW; Crippa JA; Atakan Z; McGuire PK. (Feb 2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 35:764-774. DOI.
  • Stone JM; Fusar-Poli P. (1 Nov 2009). Abnormal thalamic glutamate and liability to psychosis: State or trait marker?. SCHIZOPHRENIA RESEARCH. 115:94-95. Author weblink DOI.
  • Stone JM; Day F; Tsagaraki H; Valli I; McLean MA; Lythgoe DJ; O'Gorman RL; Barker GJ; et alMcGuire PK; OASIS. (15 Sep 2009). Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry. 66:533-539. DOI.
  • Stone JM; Davis JM; Leucht S; Pilowsky LS. (Jul 2009). Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull. 35:789-797. DOI.
  • Stone JM. (2009). Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. Curr Pharm Des. 15:2594-2602.
  • Stone JM; McLean MA; Lythgoe DJ; O'Gorman RL; Barker GJ; McGuire PK. (1 Oct 2008). Does elevated cortical glutamate release drive loss of grey matter in psychosis?. EARLY INTERVENTION IN PSYCHIATRY. 2:A2-A2. Author weblink.
  • Stone JM; Erlandsson K; Arstad E; Squassante L; Teneggi V; Bressan RA; Krystal JH; Ell PJ; et alPilowsky LS. (Apr 2008). Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study. Psychopharmacology (Berl). 197:401-408. DOI.
  • McGuire P; Howes OD; Stone J; Fusar-Poli P. (Feb 2008). Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol Sci. 29:91-98. DOI.
  • Stone JM; Pilowsky LS. (Aug 2007). Novel targets for drugs in schizophrenia. CNS Neurol Disord Drug Targets. 6:265-272.
  • Stone JM; Morrison PD; Pilowsky LS. (Jun 2007). Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review. J Psychopharmacol. 21:440-452. DOI.
  • Stone JM. (2007). Glutamatergic Dysfunction in Schizophrenia. Advances in Schizophrenia and Clinical Psychiatry. 3:34-39.
  • Stone JM; Pilowsky LS. (1 Dec 2006). Psychopathological consequences of ketamine. BRITISH JOURNAL OF PSYCHIATRY. 189:565-566. Author weblink DOI.
  • Stone JM; Arstad E; Erlandsson K; Waterhouse RN; Ell PJ; Pilowsky LS. (1 Aug 2006). [(123)I]TPCNE - A novel SPET tracer for the sigma-1 receptor: First human studies and in vivo haloperidol challenge. SYNAPSE. 60:109-117. Author weblink DOI.
  • Pilowsky LS; Stone JM. (1 Jul 2006). Untitled. EUROPEAN PSYCHIATRY. 21:347-347. Author weblink DOI.
  • Stone JM; Erlandsson K; Arstad E; Bressan RA; Squassante L; Teneggi V; Ell PJ; Pilowsky LS. (Feb 2006). Ketamine displaces the novel NMDA receptor SPET probe [(123)I]CNS-1261 in humans in vivo. Nucl Med Biol. 33:239-243. DOI.
  • Pilowsky LS; Bressan RA; Stone JM; Erlandsson K; Mulligan RS; Krystal JH; Ell PJ. (1 Feb 2006). First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. MOLECULAR PSYCHIATRY. 11:118-119. Author weblink DOI.
  • Stone JM; Pilowsky LS. (Jan 2006). Antipsychotic drug action: targets for drug discovery with neurochemical imaging. Expert Rev Neurother. 6:57-64. DOI.
  • Stone JM; Bressan RA; Erlandsson K; Ell PJ; Pilowsky LS. (Aug 2005). Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride. Psychopharmacology (Berl). 180:664-669. DOI.
  • Bressan RA; Erlandsson K; Stone JM; Mulligan RS; Krystal JH; Ell PJ; Pilowsky LS. (1 Jul 2005). Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo. Biol Psychiatry. 58:41-46. DOI.
  • Stone J; Szmukler G. (2002). An Audit of Risk Assessment in an Emergency Setting. Psychiatric Bulletin. 26:88-90.
  • Stone J; Ohlsen R; Taylor D; Pilowsky L. (2002). A Naturalistic Study of the Antipsychotic Medication Review Service at the Maudsley Hospital. Psychiatric Bulletin. 26:291-294.
  • Hartley A; Stone JM; Heron C; Cooper JM; Schapira AH. (Nov 1994). Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem. 63:1987-1990.

Chapters in books

  • Stone JM; Arstad E. Receptors and Transporters. In Sampson's Textbook of Radiopharmacy. 251-262. Theobald A (ed). Pharmaceutical Press (25 Feb 2010).
  • Stone JM; Pilowsky LS. Dopamine: Neuroleptics. In Encyclopedia of Neuroscience. 485-491. Squire LR (ed). Academic Press (28 May 2009).
  • Stone J; Pilowsky L. Schizophrenia and psychotic disorder. In Nuclear medicine in psychiatry. 301-310. Otte AP (ed); Audenaert K (ed); Peremans K (ed). Springer Verlag (2004).
  • Stone JM; Pilowsky LS. Monitoring Treatment Effects. In Psychiatric neuroimaging. 156-160. Ng V (ed); Barker GJ (ed); Hendler T (ed). Ios Pr Inc (2003).

Conferences

  • Carhart-Harris R; Erritzoe D; Stone J; Wise RG; Nutt D. The functional brain correlates of the psychedelic state: an arterial spin labelling study with psilocybin. 24th Congress Meeting of European-College-of-Neuropsychopharmacology, 3 Sep 2011 - 7 Sep 2011. 21:S313-S313. ELSEVIER SCIENCE BV (1 Sep 2011). Author weblink.
  • Stone JM; Dietrich C; Reed L; Edden R; De Simoni S; Mehta MA; Krystal J; Barker G. EFFECT OF KETAMINE ON BRAIN GLUTAMATE AND GABA IN HEALTHY VOLUNTEERS. Summer Meeting of the British-Association-for-Psychopharmacology, 24 Jul 2011 - 27 Jul 2011. 25:A59-A59. SAGE PUBLICATIONS LTD (1 Aug 2011). Author weblink.
  • Brugger S; Davis JM; Qu J; Stone JM. D2 RECEPTOR OCCUPANCY BY ANTIPSYCHOTIC DRUGS: A META-ANALYSIS OF PET AND SPECT STUDIES. Summer Meeting of the British-Association-for-Psychopharmacology, 24 Jul 2011 - 27 Jul 2011. 25:A42-A42. SAGE PUBLICATIONS LTD (1 Aug 2011). Author weblink.
  • Carhart-Harris RL; Erritzoe DE; Williams TM; Stone JM; Reed L; Tyacke R; Wise RG; Nutt DJ. DECREASED CEREBRAL BLOOD FLOW AFTER INTRAVENOUS PSILOCYBIN. Summer Meeting of the British-Association-for-Psychopharmacology, 24 Jul 2011 - 27 Jul 2011. 25:A39-A39. SAGE PUBLICATIONS LTD (1 Aug 2011). Author weblink.
  • McGuire P; Valli I; Fusar-Poli P; Allen P; Egerton A; Howes O; Stone J. GLUTAMATE IN THE EARLY PHASE OF PSYCHOSIS. 13th International Congress on Schizophrenia Research (ICSR), 2 Apr 2011 - 6 Apr 2011. 37:126-127. OXFORD UNIV PRESS (1 Mar 2011). Author weblink.
  • McGuire P; Fusar-Poli P; Broome M; Roiser J; Chaddock C; Valli I; Carletti F; Howes O; et alEgerton A; Stone J; Woolley J; Mechelli A; Allen P. NEUROIMAGING STUDIES IN SUBJECTS AT ULTRA HIGH RISK OF PSYCHOSIS. 13th International Congress on Schizophrenia Research (ICSR), 2 Apr 2011 - 6 Apr 2011. 37:146-146. OXFORD UNIV PRESS (1 Mar 2011). Author weblink.
  • McGuire P; Allen P; Howes O; Stone J; Tognin S; Riecher A; Meisenzahl E; Koutsouleris N; et alPantelis C; McGorry P; Broome M; Valli I; Woolley J; Carletti F; Egerton A; Barker G; Mechelli A. CAN WE USE NEUROIMAGING DATA TO PREDICT TRANSITION TO PSYCHOSIS?. 13th International Congress on Schizophrenia Research (ICSR), 2 Apr 2011 - 6 Apr 2011. 37:171-172. OXFORD UNIV PRESS (1 Mar 2011). Author weblink.
  • Nottage J; Ffytche D; Stone J; McGuire P; Murray R; Morrison PD. THE EFFECT OF INTRAVENOUS SYNTHETIC THC ON RESTING STATE EEG BELOW AND ABOVE 20HZ. 13th International Congress on Schizophrenia Research (ICSR), 2 Apr 2011 - 6 Apr 2011. 37:39-39. OXFORD UNIV PRESS (1 Mar 2011). Author weblink.
  • Stone JM; Bhattacharyya S; Barker G; McGuire PK. Substance use and regional grey matter volume in individuals at high risk of psychosis. European-College-of-Neuropsychopharmacology Workshop on Neuropsychopharmacology for Young Scientists in Europe, 3 Mar 2011 - 6 Mar 2011. 21:S63-S64. ELSEVIER SCIENCE BV (1 Mar 2011). Author weblink DOI.
  • Dunn JT; Baker SX; Stone J; Cleij M; Marsden PK; O'Doherty M; Reed LJ. DIFFERENTIAL OCCUPANCY OF STRIATAL VERSUS EXTRASTRIATAL DOPAMINE D2/D3 RECEPTORS BY THE TYPICAL ANTIPSYCHOTIC HALOPERIDOL IN MAN MEASURED USING I [18F]-FALLYPRIDE PET. Summer Meeting of the British-Association-for-Psychopharmacology, 25 Jul 2010 - 28 Jul 2010. 24:A33-A33. SAGE PUBLICATIONS LTD (1 Aug 2010).
  • Stone JM; Bhattacharyya S; Barker GJ; McGuire PK. SUBSTANCE USE AND REGIONAL GREY MATTER VOLUME IN INDIVIDUALS AT HIGH RISK OF PSYCHOSIS. Summer Meeting of the British-Association-for-Psychopharmacology, 25 Jul 2010 - 28 Jul 2010. 24:A58-A58. SAGE PUBLICATIONS LTD (1 Aug 2010). Author weblink.
  • Stone J. GLUTAMATE IN THE AT RISK MENTAL STATE. 2nd Conference of the Schizophrenia-International-Research-Society (SIRS), 10 Apr 2010 - 14 Apr 2010. 117:168-168. ELSEVIER SCIENCE BV (1 Apr 2010). Author weblink DOI.
  • Valli I; Stone JM; Mechelli A; Bhattacharyya S; Raffin M; Poli PF; Allen P; Seal ML; et alMcGuire PK. ALTERED MEDIAL TEMPORAL ACTIVATION RELATED TO LOCAL GLUTAMATE IN SUBJECTS WITH PRODROMAL SIGNS OF PSYCHOSIS. 2nd Conference of the Schizophrenia-International-Research-Society (SIRS), 10 Apr 2010 - 14 Apr 2010. 117:533-533. ELSEVIER SCIENCE BV (1 Apr 2010). Author weblink DOI.
  • Wilson DA; Sumich AL; Bhattacharyya S; Ffytche D; Stone J; Nottage J; Tunstall N; Kapur S; et alMcGuire P; Murray R; Morrison PD. THE EFFECTS OF INTRAVENOUS SYNTHETIC Delta 9-TETRAHYDROCANNABINOL ON P300 AND N300 EVENT-RELATED POTENTIALS DURING TARGET AND NOVELTY PROCESSING. 12th International Congress on Schizophrenia Research, 28 Mar 2009 - 1 Apr 2009. 35:53-53. OXFORD UNIV PRESS (1 Mar 2009). Author weblink.
  • Nottage J; Ffytche D; Bhattacharyya S; Stone J; Sumich A; Tunstall N; Wilson D; McGuire P; et alKapur S; Morrison P. THE EFFECT OF INTRAVENOUS SYNTHETIC THC ON EEG OSCILLATIONS DURING A SELF-PACED MOTOR TASK. 12th International Congress on Schizophrenia Research, 28 Mar 2009 - 1 Apr 2009. 35:55-55. OXFORD UNIV PRESS (1 Mar 2009). Author weblink.
  • Stone JM; Pilowsky LS; Bressan R; Erlandsson K; Ell RJ; Arstad E; Squassante L; Teneggi V. Ketamine reduces NMDA receptor SPET ligand [123I]CNS1 261 VT in humans - Relationship to psychotic symptons. 62nd Annual Meeting of the Society-of-Biological-Psychiatry, 17 May 2007 - 20 May 2007. 61:127S-127S. ELSEVIER SCIENCE INC (15 Apr 2007). Author weblink.
  • Stone J; Davis JM; Leucht S; Pilowsky LS. Is antipsychotic efficacy driven by cortical dopamine receptor occupancy? An original patient data meta-analysis of SPET and PET studies. 10th International Congress on Schizophrenia Research, 2 Apr 2005 - 6 Apr 2005. 33:396-397. OXFORD UNIV PRESS (1 Mar 2007). Author weblink.
  • Teneggi V; Stone JM; Erlandsson K; Squassante L; Arstad E; Bressan RA; Ell PJ; Bye A; et alPilowsky LS. Ketamine NMDA receptor inhibition and psychotic symptoms. A SPET study in humans with a novel NMDA receptor ligand. 18th Congress of the European-College-of-Neuropsychopharmacology, 22 Oct 2005 - 26 Oct 2005. 15:S517-S517. ELSEVIER SCIENCE BV (1 Oct 2005). Author weblink.
  • Pilowsky LS; Bressan RA; Erlandsson K; Mulligan RS; Owens J; Stone J; Cunningham VJ; Gunn RN; et alEll PJ. Is the NMDA receptor relevant to antipsychotic drug action?. 59th Annual Meeting of the Society-of-Biological-Psychiatry, 29 Apr 2004 - 1 May 2004. 55:125S-125S. ELSEVIER SCIENCE INC (15 Apr 2004). Author weblink.
  • Bressan RA; Erlandsson K; Mulligan RS; Gunn RN; Cunningham VJ; Owens J; Cullum ID; Stone JM; et alEll PJ; Pilowsky LS. NMDA binding is altered in schizophrenia and modulated by antipsychotic drugs: An [(123)I]CNS 1261 study. 12th Biennial Winter Workshop on Schizophrenia, 7 Feb 2004 - 13 Feb 2004. 67:117-117. ELSEVIER SCIENCE BV (15 Feb 2004). Author weblink.
  • Stone JM; Bressan RA; Erlandsson K; Davies G; Ell PJ; Pilowsky LS. Atypical antipsychotics preferentially occupy caudate nucleus D2/D3 receptors within the striatum: A voxel-based analysis. 12th Biennial Winter Workshop on Schizophrenia, 7 Feb 2004 - 13 Feb 2004. 67:125-125. ELSEVIER SCIENCE BV (15 Feb 2004). Author weblink.
  • Bressan RA; Erlandsson K; Mulligan RS; Stone JM; Gunn RN; Cunningham VJ; Owens J; Cullum ID; et alEll PJ; Pilowsky LS. NMDA dysfunction in schizophrenia is modulated by antipsychotic drugs: A [123I]CNS 1261 study. 5th International Symposium on Functional Neuroreceptor Mapping of the Living Brain, 15 Jul 2004 - 17 Jul 2004. 22:T103-T104. ACADEMIC PRESS INC ELSEVIER SCIENCE (1 Jan 2004). Author weblink.
  • Stone JM; Bressan RA; Erlandsson K; Davies G; Ell PJ; Pilowsky LS. Intrastriatal selectivity of atypical antipsychotics: A voxel based analysis. Summer Meeting of the British-Association-for-Psychopharmacology, 20 Jul 2003 - 23 Jul 2003. 17:A49-A49. SAGE PUBLICATIONS LTD (1 Sep 2003). Author weblink.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook